Article Versions Notes

Bilbao-Meseguer I, Barrasa H, Asín-Prieto E, Alarcia-Lacalle A, Rodríguez-Gascón A, Maynar J, Sánchez-Izquierdo JÁ, Balziskueta G, Griffith MS-B, Quilez Trasobares N, et al. Population Pharmacokinetics of Levetiracetam and Dosing Evaluation in Critically Ill Patients with Normal or Augmented Renal Function. Pharmaceutics. 2021; 13(10):1690. https://doi.org/10.3390/pharmaceutics13101690

Bilbao-Meseguer, Idoia, Helena Barrasa, Eduardo Asín-Prieto, Ana Alarcia-Lacalle, Alicia Rodríguez-Gascón, Javier Maynar, José Ángel Sánchez-Izquierdo, Goiatz Balziskueta, María Sánchez-Bayton Griffith, Nerea Quilez Trasobares, and et al. 2021. "Population Pharmacokinetics of Levetiracetam and Dosing Evaluation in Critically Ill Patients with Normal or Augmented Renal Function" Pharmaceutics 13, no. 10: 1690. https://doi.org/10.3390/pharmaceutics13101690

Bilbao-Meseguer, I., Barrasa, H., Asín-Prieto, E., Alarcia-Lacalle, A., Rodríguez-Gascón, A., Maynar, J., Sánchez-Izquierdo, J. Á., Balziskueta, G., Griffith, M. S.-B., Quilez Trasobares, N., Solinís, M. Á., & Isla, A. (2021). Population Pharmacokinetics of Levetiracetam and Dosing Evaluation in Critically Ill Patients with Normal or Augmented Renal Function. Pharmaceutics, 13(10), 1690. https://doi.org/10.3390/pharmaceutics13101690